Most prostate tumors never threaten a man's life
About 1.2 million prostate cancer cases and 350,000 deaths occur each year, yet most diagnosed men have low-risk disease confined to the gland—and roughly 99 percent of them live more than a decade after diagnosis.
The disease is uncontrolled growth in the prostate, a gland below the bladder. Screening usually finds trouble first via blood prostate-specific antigen. Diagnosis needs biopsy; pathologists assign a Gleason score, and imaging checks spread. Cases are staged 1 to 4 from Gleason, PSA, and scans. Many small tumors stay quiet under active surveillance. Riskier ones may get radiation or radical prostatectomy. Disease beyond the gland is treated by cutting androgen fuel; when cells resist that approach—castration-resistant disease—hormone therapy continues with the chemotherapy drug docetaxel.
Age raises risk; average diagnosis is about 67. Family cancer history, especially BRCA2 variants, raises odds. Lifetime figures cited are one in eight men diagnosed and one in forty dying of it. Typical blood PSA sits near 1 ng/mL; below-average levels make dangerous disease over the next 8 to 10 years unlikely, while above 4 ng/mL about one in four develop cancer and above 10 ng/mL more than half do. Early disease is often silent; later urinary, sexual, or bleeding symptoms appear, though over half of men past 50 have urinary trouble from other causes such as benign enlargement.
Distant spread, especially to bone and nodes, drops five-year survival to roughly 30 to 40 percent. Screening can cut death risk in large studies but also finds cancers that would never have mattered, bringing anxiety and unnecessary procedures. Guidelines often favor counseling high-risk men and discourage routine screening after 70 or when life expectancy is under ten years. Uptake varies widely—over 80 percent of men screened in the US and Western Europe versus about 20 percent in Japan.
Source: Prostate cancer
